Why is Pfizer falling/rising?

As of 06-Aug, Pfizer Ltd. is experiencing a decline in its stock price, currently at 5,050.00, reflecting a decrease of 42.8 points or 0.84%. The stock has underperformed in the short term, with a 1-week return of -3.83% compared to the Sensex's -1.15%. Additionally, over the past month, Pfizer's stock has dropped by 12.72%, while the Sensex has only decreased by 3.46%. Despite outperforming its sector by 1.22% today, the overall performance remains weak, with a falling investor participation indicated by a 12.06% drop in delivery volume against the 5-day average. However, the company boasts a high management efficiency with a return on equity of 19.67% and a low debt-to-equity ratio, which may provide some support to investor confidence.
Broader Market Context: The broader market context shows that the Pharmaceuticals & Drugs sector has declined by 2.17%, contributing to the negative sentiment surrounding Pfizer. While the stock has shown resilience over a longer time frame, with a 20.49% increase over the past three years, its year-to-date performance is down by 3.89%, contrasting sharply with the Sensex's gain of 3.08%. This divergence highlights the challenges Pfizer faces in the current market environment, despite its strong operational metrics and high dividend yield of 3.93%, which could attract some investors looking for income amidst the volatility.